Banamine-S Injectable Solution 50mg/ml (100 ml) (Manufacturer may vary)

Banamine-S Injectable Solution is indicated for the control of pyrexia associated with swine respiratory disease. Each ml of Banamine-S Injectable Solution contains flunixin meglumine equivalent to 50 mg flunixin. The recommended dosage of Banamine-S for swine is 2.2 mg per kg (2 ml per 100 lbs) body weight given by IM injection in the neck. Do not administer more than 10 ml per injection site. Not for use in breeding swine. Flunixin meglumine.

Key Benefits

• Respiratory disease typically triggers a fever
• Fever commonly reduces appetite
• Reduced appetite diminishes performance
• Banamine-S injectable solution can reverse this process, so pigs can get back on feed

Advantages

Reduces fever in pigs with respiratory disease.

• Quickly absorbed for a rapid fever reduction¹
• The original flunixin meglumine anti-inflammatory is FDA-approved for reducing fevers associated with swine respiratory disease
• A potent non-steroidal anti-inflammatory drug (NSAID), having both analgesic and anti-fever properties

Indications:

Banamine-S (flunixin meglumine injection) is indicated for the control of pyrexia associated with swine respiratory disease.

Banamine Injectable Solution is a registered trademark of Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co. Inc.

The recommended dose for swine is 2.2 mg/kg (1 mg/lb; 2 mL per 100 lbs) body weight given by a single intramuscular administration. The injection should be given only in the neck musculature with a maximum of 10 mL per site.

USE WITHIN 28 DAYS OF FIRST PUNCTURE AND PUNCTURE A MAXIMUM OF 10 TIMES. WHEN USING A DRAW-OFF SPIKE OR NEEDLE WITH BORE DIAMETER LARGER THAN 18 GAUGE, DISCARD ANY PRODUCT REMAINING IN THE VIAL IMMEDIATELY AFTER USE.

Note: Intramuscular injection may cause local tissue irritation and damage. In an injection-site irritation study, the tissue damage did not resolve in all animals by Day 28 post-injection. This may result in trim loss of edible tissue at slaughter.

Contraindications

There are no known contraindications to this drug in swine when used as directed. Do not use in animals showing hypersensitivity to flunixin meglumine. Use judiciously when renal impairment or gastric ulceration is suspected.

Residue Warnings

Swine must not be slaughtered for human consumption within 12 days of the last treatment.

Caution:

Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Precautions

As a class, cyclo-oxygenase inhibitory NSAIDs may be associated with gastrointestinal, renal and hepatic toxicity. Sensitivity to drug-associated adverse events varies with the individual patient. Patients at greatest risk for adverse events are those that are dehydrated, on concomitant diuretic therapy, or those with existing renal, cardiovascular, and/or hepatic dysfunction. Concurrent administration of potentially nephrotoxic drugs should be carefully approached. NSAIDs may inhibit the prostaglandins that maintain normal homeostatic function. Such prostaglandin effects may result in clinically significant disease in patients with underlying or pre-existing disease that has not been previously diagnosed.

Since many NSAIDs possess the potential to produce gastrointestinal ulceration, concomitant use of flunixin meglumine with other anti-inflammatory drugs, such as other NSAIDs and corticosteroids, should be avoided.

Not for use in breeding swine. The reproductive effects of Banamine-S (flunixin meglumine injection) have not been investigated in this class of swine.

Intramuscular injection may cause local tissue irritation and damage. In an injection site irritation study, the tissue damage did not resolve in all animals by Day 28 post-injection. This may result in trim loss of edible tissue at slaughter.

Adverse Reactions

Flunixin was mildly irritating at the injection sites. No other flunixin-related changes (adverse reactions) were noted in swine administered a 1X (2.2 mg/kg; 1.0 mg/lb) dose for 9 days.

Animal Safety

Minimal toxicity manifested itself as statistically significant increased spleen weight at elevated doses (5X or higher daily for 9 days) with no change in normal microscopic architecture.

Storage:

Store at or below 25°C (77°F). Do not freeze.

Note: Intramuscular injection may cause local tissue irritation and damage. In an injection-site irritation study, the tissue damage did not resolve in all animals by Day 28 post-injection. This may result in trim loss of edible tissue at slaughter.